Ciloxan

Quick links to important sections

Ciloxan

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciloxan

Property Description
Active ingredient Ciprofloxacin hydrochloride
Form Sterile Solution (Drops) or Ointment
Pharmacological class Fluoroquinolone Antibiotic
Common purpose To eliminate bacterial infections
Origin Synthetic antibacterial agent
Differentiating Feature Topical formulation targeting ophthalmic and otic use

Ciloxan: Definition and Pharmacological Identity

The medicinal entity known as Ciloxan is a specialized, prescription-only topical antimicrobial agent. Its core activity is provided by the active ingredient, Ciprofloxacin, a substance belonging to the highly potent Fluoroquinolone class of antibiotics. Fluoroquinolones are recognized for their bactericidal mechanism, a property that ensures the active killing of bacterial cells rather than just slowing their growth. Pharmacological studies confirm Ciprofloxacin's effectiveness as a broad-spectrum agent against a significant number of pathogens.


Composition, Origin, and Topical Form

The core substance, Ciprofloxacin, is a completely synthetic antibacterial agent, chemically manufactured rather than naturally derived. Ciloxan is primarily differentiated by its formulation exclusively for Topical administration, requiring direct application to the infected site, and is prepared as a sterile liquid solution (eye drops or ear drops) or an ointment. This specialized, non-systemic delivery ensures the drug is highly focused, working where the infection is located while minimizing widespread impact on the body.


General Purpose of this Topical Antibiotic

The general therapeutic purpose of Ciloxan is to eliminate the harmful bacteria causing a localized infection. By applying this potent bactericidal agent directly to the infected area, the medication addresses the microbial root cause. This focused, high-efficacy action is intended to resolve the underlying bacterial infection and clear the microbial load within the targeted ocular or otic tissue.

What side effects are possible with Ciloxan?

Possible Side Effects and Safety Information

The safety profile of Ciloxan (ciprofloxacin ophthalmic/otic) is formally documented in regulatory materials, distinguishing between common local effects and rare, serious systemic reactions associated with the fluoroquinolone class. The most frequently observed adverse reactions are generally localized to the application site.


Frequency-Classified Adverse Reactions

Adverse reactions are classified according to their incidence as reported in official clinical data:

  • Very Common: Ocular discomfort, dysgeusia (taste perversion).
  • Common: Corneal deposits or crystalline precipitates, foreign body sensation, ocular hyperaemia (redness), itching (pruritus), and crusting of the eyelid margin.
  • Uncommon: Headache, nausea, blurred vision, dry eye, increased lacrimation, photophobia, and swelling of the eyelid (oedema).

System-Organ Classes and Safety Notes

The effects are grouped by affected systems, predominantly Eye disorders. Less frequent effects are reported in the Nervous system (e.g., headache) and Gastrointestinal system (e.g., nausea).

Serious Adverse Reactions include the potential for hypersensitivity reactions (including anaphylaxis) associated with the systemic quinolone class, which necessitate immediate discontinuation. Rarely, corneal perforation has been documented, particularly in the presence of severe pre-existing corneal damage. Due to the class association, the possibility of tendon disorders is noted in the official label.

Exposure-Related Patterns: In patients with corneal ulcers, the appearance of white crystalline precipitates may occur within the first week of frequent dosing. As with all antibacterial preparations, prolonged use carries the regulatory risk of superinfection by non-susceptible organisms, including fungi.

Contraindications: Use is prohibited in individuals with a known history of hypersensitivity to ciprofloxacin, any other quinolones, or any component of the medication.

Overdose and Emergency Response

The official regulatory documentation for Ciloxan (ciprofloxacin topical solution) defines the overdose profile based on the formulation’s low systemic absorption and the mandated emergency response to severe hypersensitivity events.

Overdose Scope and Documented Presentations

Acute Local Overdose: Due to the product’s characteristics, no significant toxic effects are expected from an acute ocular or otic over-application of the solution. Similarly, the accidental ingestion of the contents of a single bottle is not expected to cause toxic effects.

Life-Threatening Outcomes: The highest documented risk requiring immediate action relates to the potential for serious and occasionally fatal hypersensitivity (anaphylactic) reactions associated with the fluoroquinolone drug class. These reactions are classified as severe and may present with cardiovascular collapse, loss of consciousness, dyspnea, pharyngeal or facial edema, and urticaria.

Emergency Response and Seeking Help

When Immediate Medical Help is Required: Regulatory documents mandate that individuals seek immediate medical attention for any sign of a serious allergic reaction, as serious acute hypersensitivity reactions may require immediate emergency treatment. The product should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.

Management Procedures: If an ocular overdose occurs, the affected eye(s) may be flushed with lukewarm tap water. The general management of overdose is officially directed as symptomatic and supportive treatment. Emergency treatment may include epinephrine and other resuscitation measures (such as oxygen and intravenous fluids) as clinically indicated for managing life-threatening systemic effects. No specific antidote is explicitly named in the regulatory labeling.

Therapeutic Uses of Ciloxan

What Ciloxan Treats: Main Uses and Benefits

Ciloxan (ciprofloxacin ophthalmic solution) is a medication commonly used to help with conditions associated with acute or disruptive episodes, such as bacterial infections of the eye. Its core therapeutic domain, which addresses conditions presenting with systemic or localized discomfort, includes treating specific bacterial manifestations like corneal ulcers and bacterial conjunctivitis. The product is considered relevant in these scenarios where short-term symptomatic assistance is needed.

The formulation is applied across domains where additional symptomatic support is needed, particularly in clinical scenarios marked by temporary physiological imbalance due to infection. It may assist with managing symptom clusters that become intense or disruptive, such as redness, pain, and excessive discharge. This supportive relief contributes to improved comfort during periods of heightened symptoms. It contributes to easing the overall symptom load, which helps patients cope more steadily with symptom fluctuations.

“This application supports patients during episodes of heightened discomfort.”

Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Ciprofloxacin Ophthalmic

Eligibility and Restrictions for Use

The eligibility for Ciloxan (ciprofloxacin ophthalmic/otic) is strictly defined by regulatory documents, focusing on absolute contraindications and specific population limitations.

Contraindicated Populations

Use of this medicine is absolutely prohibited for patients with:

  • Hypersensitivity to Ciprofloxacin: A known allergy to the active substance.
  • Hypersensitivity to Quinolones: A history of allergic reaction to any other antibiotic in the quinolone class.

Age-Related Eligibility Rules

Population Group Eligibility Status (Topical Use) Restriction Basis
Adults and Older Adults Permitted. Established use; no specific limitations.
Children ge 1 Year Permitted. Safety and effectiveness are generally established.
Infants < 1 Year Not Recommended. Safety and effectiveness have not been established for this age group.

Conditional and Limited Use

Use is restricted or requires caution under certain circumstances, as stated in official labeling:

  • Pregnancy and Lactation: Use during pregnancy is conditional and advised only if the potential benefit justifies the potential risk to the fetus. For breastfeeding, caution is exercised as excretion into human milk is unknown and a risk to the nursing child cannot be excluded.
  • Organ Impairment: Eligibility is limited in patients with renal or hepatic impairment, as no studies have been performed using this topical formulation in these specific patient populations.
  • Tendon Issues: Treatment must be discontinued at the first sign of tendon inflammation, reflecting a conditional restriction linked to warnings for systemic quinolones.
  • Contact Lens Wear: Patients with an ocular infection should not wear contact lenses during treatment with the ophthalmic solution.

What should I know about interactions with other medicines?

Ciloxan Interactions with other medicines and products

Official regulatory information for Ciloxan (ciprofloxacin topical) notes that specific drug interaction studies have not been conducted with this formulation due to its localized use and low anticipated absorption into the body. Therefore, documented interaction information primarily references effects known to occur with the systemic use of its active ingredient, Ciprofloxacin, an antibiotic in the Fluoroquinolone class.

Formally Documented Interaction Patterns

Classification Interacting Substance/Class Regulatory Finding/Requirement
Timing Restriction Other Topical Ophthalmic Products Must be administered at least 5 minutes apart to ensure proper retention.
Systemic Contraindication Tizanidine Co-administration with systemic Ciprofloxacin is contraindicated.
Exposure Modification Theophylline, Caffeine Systemic Ciprofloxacin may elevate plasma concentrations of Theophylline and interfere with Caffeine metabolism.
Pharmacodynamic Risk Oral Anticoagulants (e.g., Warfarin) Systemic Ciprofloxacin has been shown to enhance the effects of these medicines.

Population-Specific Notes

The risk of Tendon inflammation and rupture, which is associated with systemic Ciprofloxacin, may be increased in elderly patients who are concurrently treated with Corticosteroids.

Mechanism of Action

The mechanism of Ciprofloxacin, the active ingredient in Ciloxan, is defined by its ability to induce lethal damage to bacterial cells, resulting in a bactericidal effect.

Dual Inhibition of Bacterial Genetic Replication

The drug operates by directly targeting two critical enzymes unique to bacteria: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for maintaining the structure of the bacterial chromosome during replication and cell division. Ciprofloxacin acts as an inhibitor by binding to and stabilizing the enzyme-DNA complex after the DNA strands have been cut. This mechanism prevents the DNA from being re-ligated, which interrupts the replication process.

Induction of Lethal DNA Damage

This trapping mechanism leads directly to the accumulation of Double-Strand Breaks (DSBs) across the bacterial genome. The resulting genomic instability triggers a failure in the bacterial cell's repair systems, leading to programmed cell death. This process results in the physiological elimination of the susceptible microbial population at the site of application.

Constraint by Target-Mediated Resistance

The effectiveness of this mechanism can be physiologically reduced by bacterial defense strategies, specifically point mutations in the genes encoding the target enzymes (gyrA and parC). These mutations lessen the binding affinity of Ciprofloxacin. Additionally, efflux pumps may actively expel the drug, limiting the concentration available to induce the lethal damage.

Dosage and Administration Information

Official Administration Guidelines

Ciloxan (ciprofloxacin) is strictly for topical use and is available as a 0.3% ophthalmic solution (drops) or ointment. The solution is explicitly not for injection into the eye. The medicine is used according to specific, non-constant dosing schedules that vary by the condition being addressed.

Labeled Dosing Regimens (Ophthalmic Solution)

Condition Initial High-Frequency Use Maintenance Use & Duration
Corneal Ulcers 2 drops every 15 minutes for 6 hours, then 2 drops every 30 minutes for the remainder of Day 1. 2 drops hourly on Day 2; then 2 drops every 4 hours from Day 3 through Day 14. Treatment may be continued past 14 days.
Bacterial Conjunctivitis 1 to 2 drops every 2 hours while awake for the first 2 days. 1 to 2 drops every 4 hours while awake for the next 5 days.

Dosing for Other Forms and Routes

For the ophthalmic ointment (0.3%), the standard use for bacterial conjunctivitis is a 1/2-inch ribbon applied three times a day for the initial two days, reducing to two times a day for the following five days. For otic use, ciprofloxacin drops are typically instilled twice daily for a course duration of seven to ten days.

Procedural Administration Constraints

  • Contact Lenses: Must be removed before application; reinsertion is permitted at least 15 minutes later.
  • Sequential Drops: When administering multiple topical eye products, they must be separated by a minimum interval of five minutes.
  • Otic Use: The solution should be warmed by holding the container in the hand prior to instillation to minimize potential dizziness, and the patient must lie with the affected ear upward to facilitate penetration.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ciloxan

Evidence for Use in Bacterial Corneal Ulcers (Ophthalmic)

Research exploring topical ciprofloxacin for bacterial corneal ulcers was evaluated in Randomized Controlled Trials (RCTs) and Multicenter Clinical Trials for conditions associated with acute or disruptive episodes. These studies involved both adults and children (≥ 1 year old) and examined outcomes related to clinical success/cure rate, which involves a physician’s determination that the infection has resolved, and the bacteriological eradication rate, which measures the clearance of the specific causative bacteria. Studies monitored outcomes linked to inflammatory or irritative states, and clinical resolution was tracked across major trials in this area. Long-term visual outcomes are not consistently well-characterized across all available evidence.


Evidence for Use in Acute Bacterial Conjunctivitis (Ophthalmic)

For acute bacterial conjunctivitis, research has explored the use of ciprofloxacin drops in a number of RCTs, including trials comparing the drug to a non-active substance (placebo) or other standard antibiotics. Studies included populations of adults and children (≥ 1 month old) and tracked the time until clinical resolution (reduction in signs like redness and discharge) and the elimination of the bacterial pathogen. Microbial eradication was an outcome tracked and reported across many of the available comparator and placebo-controlled trials. Comparative evidence is lacking or limited for certain specific subgroups of patients.


Evidence for Use in Acute Otitis Externa and Otitis Media with Tubes (Otic)

Research examined the use of topical ciprofloxacin for ear infections, including Acute Otitis Externa (AOE) and Acute Otitis Media with Tympanostomy Tubes (AOMT) in children. Studies were evaluated in RCTs and primarily included populations of adults and children (≥ 6 months old). Researchers studied outcomes related to physical discomfort, tracking the clinical cure rate and the time until symptoms cease. For AOMT, the evidence often involved ciprofloxacin combined with a steroid component, meaning the reported outcomes are linked to the performance of the combination. Follow-up durations were limited, making long-term effects not fully established.

Key Studies & References

  1. Topical antibiotics for acute bacterial conjunctivitis: a systematic review
  2. Prescribing Guidelines for Acute Otitis Externa and Otitis Media with Tympanostomy Tube Otorrhea - Nationwide Children's Hospital (For combined product use in special population)

Frequently Asked Questions (FAQ)

Common questions about Ciloxan (FAQ)

Q: Why does Ciloxan come in both drops and ointment? What's the difference?

A: Ciloxan is available as both an ophthalmic solution (drops) and an ointment. The difference in formulation determines its approved uses and application frequency. According to official product information, the drops are approved for treating both corneal ulcers and bacterial conjunctivitis, while the ointment form is typically indicated only for bacterial conjunctivitis.

Q: What if the Ciloxan drops look cloudy or change color?

A: Regulatory documents describe the ophthalmic solution as a sterile, clear liquid. Although official information notes that a side effect called 'corneal deposits' can sometimes appear on the eye itself during frequent use, the solution in the bottle should not be cloudy or change color. If you notice a change in the product's appearance, official regulatory text states that a health professional should be consulted.

Q: Does using Ciloxan cause blurry vision temporarily?

A: Official information indicates that temporary blurred vision is an uncommon side effect of the drops. It is also noted that visual disturbances, such as blurred vision that occurs right after administration, may affect a person's ability to drive or use machines. Regulatory documents state that if temporary blurred vision occurs, activities requiring sharp sight should be postponed until vision is clear.

Q: Is it normal to feel a stinging or burning sensation when I put in the drops?

A: Official safety documents list ocular discomfort and a foreign body sensation as very common adverse reactions. Reports also note that burning or stinging of the eye is a side effect experienced by users. Official reports describe this reaction as typically mild and transient.

Q: Does the use of Ciloxan carry a risk of tendinitis or tendon rupture, like the oral version?

A: Ciloxan belongs to the fluoroquinolone class of antibiotics, which is associated with tendon inflammation and rupture when taken systemically (by mouth). While the risk is much lower with topical use, official labels note that treatment must be discontinued at the first sign of tendon inflammation due to this class-wide warning. The risk is noted as being potentially increased in older patients treated concurrently with corticosteroids.

Q: Is Ciloxan drops the same as Ciprofloxacin pills?

A: Both the drops and the pills contain the same active ingredient, Ciprofloxacin, but they are different dosage forms. Ciloxan is a topical ophthalmic/otic solution for local use, whereas the pill form is for systemic use (taken by mouth).

Q: Are there official warnings about sun exposure while using Ciloxan?

A: Regulatory consumer information advises patients to avoid excessive exposure to sunlight while using the eye drops. This caution is due to the potential for phototoxicity, which means the skin may become more sensitive to the sun.

Q: What are the typical indications for the ointment form of Ciloxan?

A: The ophthalmic ointment formulation of Ciloxan is officially indicated for the treatment of bacterial conjunctivitis, which is a bacterial infection of the eye. The ointment is not indicated for treating corneal ulcers; the drops are indicated for that use.

Q: Can pregnant individuals use Ciloxan, or is it discouraged?

A: Official labeling states that use during pregnancy is conditional. It is advised only if the potential benefit to the mother is determined to justify the potential risk to the fetus. Official labeling states the decision to use the drug is based on the prescribing professional’s assessment of the benefit versus the potential risk.

Q: Can I wear my soft contact lenses while being treated with Ciloxan?

A: Official administration instructions state that contact lenses must be removed before the application of the drops, and reinsertion is permitted at least 15 minutes later. Additionally, regulatory warnings advise that contact lenses should not be worn at all while a patient has an active eye infection.

Q: Can Ciloxan be used for ear infections, or is it just for eyes?

A: Ciloxan topical formulations can be used for both the eye (ophthalmic use) and the ear (otic use). It is approved for various external ear infections, such as Acute Otitis Externa, caused by susceptible bacteria.

Q: Is there a generic version of Ciloxan available?

A: The active ingredient in Ciloxan, Ciprofloxacin ophthalmic, is available from various manufacturers in generic forms.

Q: What is the shelf life of Ciloxan after the bottle has been opened?

A: Official instructions require the ophthalmic solution to be discarded 28 days after the bottle is first opened.

Q: What happens if I accidentally swallow a small amount of the drops?

A: Due to the characteristics of the topical drops and their low concentration, official safety information indicates that no toxic effects are expected from accidentally swallowing the small amounts of the solution that might occur during normal use.

Q: Can using Ciloxan cause dry eyes?

A: Yes, regulatory documents list 'dry eye' as an uncommon adverse reaction that was reported during clinical trials. It is grouped with other less frequent side effects like blurred vision and headache.

Q: Are there any common over-the-counter medicines that are known to interact with Ciloxan?

A: The topical formulation is not known to have extensive drug interaction studies. Due to its low systemic absorption into the body, the occurrence of interactions with other medicines, including common over-the-counter products, is considered unlikely to be a major risk.

Q: Is a fungal infection covered by Ciloxan's activity?

A: Ciloxan is an antibacterial agent, not an antifungal agent. Official warnings state that prolonged use of the drug may result in the overgrowth of organisms that are not susceptible to the medicine, including fungi. If a superinfection occurs, the regulatory label indicates that appropriate treatment for the new infection should be considered.

Q: Is it necessary to shake the Ciloxan bottle before use?

A: Administration guidelines for the ophthalmic solution do not generally include an instruction to shake the bottle. For otic (ear) use, the solution should be warmed by holding the container in the hand before it is administered.

Q: Is there a warning about using Ciloxan with corticosteroid eye drops?

A: Regulatory documents mention that the serious class warning for tendon issues may be increased in older patients who are treated concurrently with corticosteroids taken systemically. However, there is no specific warning or contraindication against using the topical Ciloxan drops alongside topical corticosteroid eye drops.

Q: Can Ciloxan affect my ability to drive or operate machinery?

A: Official information states that the medication has no or negligible influence on the ability to drive or use machines. The exception is if temporary blurred vision occurs immediately after administration. If this happens, you should wait until your vision clears completely before performing activities that require sharp sight.

Q: Is Ciloxan known to cause a metallic taste after administration?

A: Yes, official safety information lists 'dysgeusia' as a very common adverse reaction. Dysgeusia is the clinical term for a disturbance of the sense of taste, which is often described by patients as a bitter or metallic taste following the use of eye drops.

Q: Has Ciloxan been studied in older adults (geriatric population)?

A: Appropriate studies have been conducted to date, and official information indicates they have not demonstrated problems that would limit the usefulness of the eye drops specifically in older patients. Generally, use is established and permitted for the geriatric population.

How should Ciloxan be stored and disposed of?

Storage and Disposal Instructions for Ciloxan

Ciloxan (ciprofloxacin ophthalmic solution) must be stored at controlled room temperature, specifically 25 C (77 F), with excursions allowed between 15 C and 30 C. It is required to protect the solution from light and it must not be refrigerated or frozen.

Container and Shelf-Life Rules

  • The bottle must be kept tightly closed and the product should be retained in its original carton.
  • To maintain stability, the solution must be discarded 28 days after first opening.
  • The medicine must be kept out of the reach of children.

Waste Handling

Do not dispose of this product via wastewater or household waste. Unused or expired medication must be discarded according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciloxan found in:

A-Z Index: